← Back to Search

Treatment for Aneurysm

N/A
Recruiting
Led By Scott Cameron, MD, PhD
Research Sponsored by The Cleveland Clinic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 10 years
Awards & highlights

Summary

This is a study of biomarkers obtained from prospectively collected subject samples and their correlation with cardiovascular and metabolic diseases. The purpose of this initiative is to develop an enduring tool to allow for collaborative research between clinicians at Cleveland Clinic Main Campus and basic scientists at the Lerner Research Institute. This collaboration will allow resources to be available to clinical and basic researchers alike. This tool will enable research of vascular disease in the Vascular Lab and will leverage this valuable asset to the fullest extent to allow for interdepartmental collaboration.

Eligible Conditions
  • Chronic Arterial Occlusive Disease
  • Aneurysm
  • Lymphedema
  • Arterial Dissection
  • Peripheral Arterial Disease
  • Vasospasm
  • Blood Clot
  • Thoracic Outlet Syndrome
  • Cardiovascular Disease
  • Carotid Disease
  • Venous Disease
  • Metabolic Diseases
  • Lipedema
  • Vasculitis
  • Fibromuscular Dysplasia
  • May-Thurner Syndrome

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~10 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 10 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
To collect blood, urine, and/or stool samples for biorepository

Find a Location

Who is running the clinical trial?

The Cleveland ClinicLead Sponsor
1,045 Previous Clinical Trials
1,370,175 Total Patients Enrolled
6 Trials studying Aneurysm
2,772 Patients Enrolled for Aneurysm
Scott Cameron, MD, PhDPrincipal InvestigatorThe Cleveland Clinic
1 Previous Clinical Trials
400 Total Patients Enrolled
~282 spots leftby Dec 2030